VAX-31 Phase 3 study
Latest Information Update: 01 Oct 2025
At a glance
- Drugs VAX 31 (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
Most Recent Events
- 06 Aug 2025 According to a Vaxcyte media release, subject to the results of the Phase 3 studies, which are expected to read out in 2026 and 2027, the Company plans to submit a BLA shortly following the completion of the last Phase 3 study.
- 06 Aug 2025 According to a Vaxcyte media release, Initiation of the remaining Phase 3 studies, which are shorter in duration than the non-inferiority study, is planned for 2025 and 2026.
- 06 Aug 2025 According to a Vaxcyte media release, following interactions with U.S. Food and Drug Administration (FDA) on VAX-31 adult program, including End-of-Phase 2 meeting, company finalizing Phase 3 clinical program to validate VAX-31 as potential new standard-of-Care adult PCV to prevent invasive pneumococcal disease (IPD) and pneumonia.